BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17572229)

  • 1. Characterization of nuclear matrix protein alterations associated with renal cell carcinoma.
    Cannon GM; Balasudramani M; Getzenberg RH
    Urology; 2007 Jun; 69(6):1227-30. PubMed ID: 17572229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of nuclear matrix protein alterations associated with renal cell carcinoma.
    Konety BR; Nangia AK; Nguyen TS; Veitmeier BN; Dhir R; Acierno JS; Becich MJ; Hrebinko RL; Getzenberg RH
    J Urol; 1998 Apr; 159(4):1359-63. PubMed ID: 9507884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic analysis of clear cell renal cell carcinoma. Identification of potential tumor markers.
    Sun CY; Zang YC; San YX; Sun W; Zhang L
    Saudi Med J; 2010 May; 31(5):525-32. PubMed ID: 20464042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
    Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
    Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma.
    Okamura N; Masuda T; Gotoh A; Shirakawa T; Terao S; Kaneko N; Suganuma K; Watanabe M; Matsubara T; Seto R; Matsumoto J; Kawakami M; Yamamori M; Nakamura T; Yagami T; Sakaeda T; Fujisawa M; Nishimura O; Okumura K
    Proteomics; 2008 Aug; 8(15):3194-203. PubMed ID: 18615424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential protein profiling in renal-cell carcinoma.
    Shi T; Dong F; Liou LS; Duan ZH; Novick AC; DiDonato JA
    Mol Carcinog; 2004 May; 40(1):47-61. PubMed ID: 15108329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-alpha on renal cell carcinoma cell lines by protein biochip technology.
    Nakamura K; Yoshikawa K; Yamada Y; Saga S; Aoki S; Taki T; Tobiume M; Shimazui T; Akaza H; Honda N
    Int J Oncol; 2006 Apr; 28(4):965-70. PubMed ID: 16525647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of CD44s in conventional renal cell carcinomas with renal vein or vena cava thrombosis. a retrospective evaluation of the expression of CD44s by immunohistochemical analysis in conventional RCC patients and in conventional RCC patients with renal vein or vena cava thrombosis.
    Altinel M; Arpali E; Turhan N; Gonenc F; Yazicioglu A
    Urol Int; 2008; 81(4):452-5. PubMed ID: 19077409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
    Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel epigenetic markers for clear cell renal cell carcinoma.
    Dalgin GS; Drever M; Williams T; King T; DeLisi C; Liou LS
    J Urol; 2008 Sep; 180(3):1126-30. PubMed ID: 18639284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum protein profiling to identify biomarkers for small renal cell carcinoma.
    Xu G; Hou CR; Jiang HW; Xiang CQ; Shi N; Yuan HC; Ding Q; Zhang YF
    Indian J Biochem Biophys; 2010 Aug; 47(4):211-8. PubMed ID: 21174948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma.
    Meyer HA; Tölle A; Jung M; Fritzsche FR; Haendler B; Kristiansen I; Gaspert A; Johannsen M; Jung K; Kristiansen G
    Eur Urol; 2009 Mar; 55(3):669-78. PubMed ID: 18450365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-arginine-glycine amidinotransferase, betaine-homocysteine S-methyltransferase, and neuropolypeptide H3 are diminished in renal clear cell carcinoma of humans.
    Peng JP; Zhang J; Huang HW; Wang FH; Du XJ; Luo PC
    Saudi Med J; 2011 May; 32(5):467-73. PubMed ID: 21556466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma.
    Morikawa T; Sugiyama A; Kume H; Ota S; Kashima T; Tomita K; Kitamura T; Kodama T; Fukayama M; Aburatani H
    Clin Cancer Res; 2007 Oct; 13(19):5703-9. PubMed ID: 17908959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps.
    Brünagel G; Schoen RE; Getzenberg RH
    J Cell Biochem; 2004 Feb; 91(2):365-74. PubMed ID: 14743395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma.
    Ohno Y; Izumi M; Yoshioka K; Ohori M; Yonou H; Tachibana M
    Oncol Rep; 2008 Sep; 20(3):511-6. PubMed ID: 18695899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over expression of hypoxia-inducible protein 2, hypoxia-inducible factor-1alpha and nuclear factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure.
    Konda R; Sugimura J; Sohma F; Katagiri T; Nakamura Y; Fujioka T
    J Urol; 2008 Aug; 180(2):481-5. PubMed ID: 18550099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nuclear matrix proteins differentially expressed in human prostate cancer cell lines and benign prostatic hyperplasia epithelial cell line].
    Sun TC; Xin L; Song LM; Zhou Y; Ning LF; Han LY; Guo Y; Yu HM; Wang HP
    Zhonghua Nan Ke Xue; 2012 Jul; 18(7):583-9. PubMed ID: 22994041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry.
    Siu KW; DeSouza LV; Scorilas A; Romaschin AD; Honey RJ; Stewart R; Pace K; Youssef Y; Chow TF; Yousef GM
    J Proteome Res; 2009 Aug; 8(8):3797-807. PubMed ID: 19610612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BIGH3 is overexpressed in clear cell renal cell carcinoma.
    Yamanaka M; Kimura F; Kagata Y; Kondoh N; Asano T; Yamamoto M; Hayakawa M
    Oncol Rep; 2008 Apr; 19(4):865-74. PubMed ID: 18357369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.